drugset / Trial / NCT02561702

Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease

NCT02561702

Phase 2 Completed 4 enrolled University of Rochester
RandomizedCrossoverQuadruple-blindTreatment

Summary

Charcot Marie Tooth Disease is a family of inherited peripheral neuropathies, with over 70 causative genes identified to date.1-4 Muscle cramps are frequent in CMT, affecting up to 85% of patients with some subtypes of CMT. These cramps impact quality of life and have been identified as an important therapeutic target for clinical trials in CMT.1-4 There is no FDA approved treatment for muscle cramps.5 Mexiletine is a sodium channel blocker approved for treatment of arrhythmias. As a sodium channel blocker, mexiletine offers the promise of effective therapy for muscle cramps.

Timeline

Start
2015-09
Primary completion
2016-12-31
Completion
2016-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Mexiletine Small molecule 150 mg Oral